

## **PRESS RELEASE**

**26th July, 2016**

**Baar, Switzerland and Belgrade, Serbia: Amicus S.A. announces signature of a Licensing and Supply Agreement with Laboratorios Salvat S.A. of Barcelona, Spain. The agreement gives Amicus exclusive rights to register and launch Salvat's Cetraxal range of topical otological anti-infective single compound and combinations in six countries of the Western Balkans – Albania, Federation of Bosnia & Herzegovina, Kosovo, Macedonia, Montenegro and Serbia.**

On July 22nd, 2016 Amicus S.A. of Baar, Switzerland, and Laboratorios Salvat S.A. signed a contract under which Amicus will register, launch and market Salvat's Cetraxal Monodosis (an innovative ciprofloxacin otic solution) and Cetraxal Plus (a unique otic solution combining ciprofloxacin and fluocinolone), Salvat's differentiated products for ear infections. The agreement provides for Amicus to exclusively commercialize the Cetraxal family under Salvat's TM for many years in the remaining six future EU-accession candidate countries of the Western Balkans.

"This important licensing agreement underlines Amicus' strategy to work with research-based companies across multiple countries, with new, differentiated medicines," commented Predrag Lukic, Amicus Regional Manager for the region and COO. "We are very proud to be given the opportunity to work with Salvat and the Cetraxal family, and we hope this is the beginning of a cooperation that will cover more geographies and more products," continued Lukic. "Salvat has a promising pipeline and we look forward to continued cooperation. Our relationship with Salvat is strategically important for the company."

"We are glad to expand the international commercial availability of the Cetraxal family products through a partnership with Amicus in the Western Balkans." said Alberto Bueno, CEO of SALVAT. "This is a major milestone for SALVAT as we continue to grow our presence in international markets."

Under the agreement, Amicus' six affiliates in the territory will register, commercialize, promote and provide medical support to the healthcare sector regarding the Cetraxal family of products.

### **About Laboratorios Salvat S.A.**

Laboratorios Salvat S.A. is a privately owned pharmaceutical group which is strongly committed to technological innovation and R&D. Founded in 1955, Salvat is headquartered in Barcelona, Spain and its US subsidiary, Salvat USA, is located in Miami, FL. Salvat is present in over 60 countries and keeps strengthening its international presence through the licensing of its own developments. The company is active in several different therapeutic areas, including ENT / Ophthalmology, digestive metabolism, dermatology and urology.

For more information about Salvat, please visit: [www.salvatbiotech.com](http://www.salvatbiotech.com)

### **About Amicus S.A.**

Amicus subsidiaries operate in the Balkan and Baltic countries of Croatia, Estonia, Kosovo, Latvia, Lithuania, Macedonia, Montenegro, Serbia and Slovenia. Set up in 2014, Amicus has gathered outstanding pharmaceutical, Medical Device and also OTC / consumer healthcare talent. The company specializes in representing research-based pharmaceutical, medical equipment and brand self-care brands across the West Balkans and Baltics.

For more information about Amicus, please visit: [www.amicuspharma.eu](http://www.amicuspharma.eu)

### **Contacts:**

**Maja Boskovic, Public Affairs Officer, Amicus**

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321

**Francesc Rosell, International Director, SALVAT**

frosell@salvatbiotech.com, Tel: +34 93 394 6400